Hodgkin Lymphoma
News
Diabetics have higher risk of hematologic, other cancers
A review of data from more than 19 million people indicates that diabetes significantly raises a person’s risk of developing cancer. When...
Conference Coverage
PET-driven chemo strategy helps reduce toxicity in Hodgkin lymphoma
CHICAGO – Results from the AHL2011 LYSA study show how PET findings can be used to de-escalate patients from BEACOPP to ABVD without losing out on...
Conference Coverage
Interim PET scans identify HL patients with better outcomes
CHICAGO—Interim PET scans can identify a subset of Hodgkin lymphoma (HL) patients with a better outcome suitable for de-escalation treatment after...
From the Journals
Physical inactivity linked to lymphoma risk
Individuals who engaged in exercise less than once a week over their lifetime had an increased risk of Hodgkin and non-Hodgkin lymphoma.
News
Umbralisib has ‘distinct’ safety profile
Phase 1 trial results suggest umbralisib, a PI3Kδ/CK1ε inhibitor, can be safe and active in patients with relapsed or refractory B-cell...
News
‘Long-term benefits’ with nivolumab in cHL
Nivolumab can provide “long-term benefits” in patients with relapsed or refractory classical Hodgkin lymphoma (cHL), according to researchers....
Conference Coverage
Novel targeted cancer drugs cause fewer arrhythmias
Tyrosine kinase inhibitors and other targeted agents have 40% lower cardiac arrhythmia risk than anthracycline-based regimens.
News
CHMP recommends approval for generic carmustine
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion of Carmustine Obvius, a...
News
FDA places tazemetostat trials on partial hold
The hold has halted enrollment in US-based trials of tazemetostat, but study subjects who have not experienced disease progression may continue to...
News
Art education benefits blood cancer patients
New research suggests a bedside visual art intervention (BVAI) can reduce pain and anxiety in inpatients with hematologic malignancies, including...
News
FDA approves BV plus chemo for untreated cHL
The US Food and Drug Administration (FDA) has approved brentuximab vedotin (ADCETRIS) in combination with chemotherapy for adults with previously...